Don’t miss the latest $ZVRA updates at upcoming Sept #investor conferences: Cantor Healthcare Conference – Fireside chat Sept 3, 11:30 a.m. ET H.C. Wainwright & Co. Global Investment Conference – Presentation Sept 8, 10:00 a.m. ET Listen live or on-demand: bit.ly/45GJqMs

Excited to present 4 posters at #ICIEM2025, Sept 2–6, in Kyoto, JP! Highlights include: MIPLYFFA® (arimoclomol) MOA in #NPC nominated for Best Poster New pediatric substudy data (<2 yrs) Efficacy in patients switching from placebo + miglustat to MIPLYFFA bit.ly/3Vnxsm7

#ICIEM2025 4 posters highlighted MIPLYFFA® (arimoclomol) in #NPC: Differentiated MOA recognized w/ Best Poster nom Miglustat analysis: switch from placebo to MIPLYFFA declined disease progression Up to 36 months of data: well tolerated in kids <2 yrs bit.ly/4pcFPPi

The DiSCOVER Trial is an opportunity to be part of a scientific process designed to evaluate the safety and effectiveness of celiprolol in an effort to bring a much-needed treatment option for people living with VEDS in the U.S. Learn more: bit.ly/3VDCFGu #VEDS

Honored to sponsor & attend The Ehlers-Danlos Society Int’l Scientific Symposium 2025 Sept 17–21 in Toronto, Canada. Our participation reflects our commitment to advancing new treatment options for #VEDS & supporting progress for the greater #EDS/#HSD community. bit.ly/488acjB

Proud to sponsor & attend @SVMtweets 2025 Vascular Scientific Sessions Sept 18–21, in Philadelphia. We share the mission of advancing vascular medicine & patient care as we develop celiprolol for the potential treatment of #VEDS. bit.ly/4nyVFSK #RareDisease #VSS2025

From the podium to the poster hall, #ICIEM2025 was an incredible opportunity to share our progress in #NPC. We presented 4 posters highlighting our foundational treatment + commitment to better options for patients. Grateful to the #NPC community. #RareDisease

Join the @Zevratx team at the Society for Vascular Medicine | SVM Vascular Scientific Sessions! Learn more below. #VSS2025

The DiSCOVER Trial is designed to make it as convenient & easy as possible to participate. Start by finding out if you meet the requirements to enroll the trial. Just complete the short, online questionnaire. Learn more: bit.ly/3VDCFGu #VEDS #RareDisease #ClinicalTrial

Thank you to the The Ehlers-Danlos Society for hosting the 2025 Int’l Scientific Symposium. We’re grateful to the #VEDS community, whose strength inspires advancement of celiprolol in an effort to bring a much-needed treatment option for people living with #VEDS in the U.S. #RareDisease

At #SVM2025, we were inspired by the strength of the #VEDS community. During #VEDSActionMonth, we’re proud to stand with patients, caregivers & advocates as we work toward new treatment options.

This week at #CNS2025, @Zevratx will share clinical data from MIPLYFFA® (arimoclomol) in #NPC and OLPRUVA® (sodium phenylbutyrate) in #UCDs across three poster presentations. Details here: bit.ly/4hcACn7

October is #VEDSActionMonth. At Zevra, we honor the strength of #VEDS patients, families and advocates working tirelessly to raise awareness and drive progress. Together, we can shine a light on this #raredisease and push for better care and treatments.

October is #NiemannPickAwareness Month. We stand with NPC patients, families and advocates working tirelessly to raise awareness and push for progress. Your strength inspires hope and drives our mission to expand global access to our foundation #NPC treatment. #RareDisease pic.x.com/7jqIeHWRbU

The DiSCOVER Trial is an opportunity to be part of a scientific process designed to evaluate the safety and effectiveness of celiprolol in an effort to bring a much-needed treatment option for people living with VEDS in the U.S. Learn more bit.ly/3VDCFGu #VEDSActionMonth

On #GlobalNPCAwarenessDay, we honor the strength of the Niemann-Pick disease type C community and remain dedicated to expanding global access to our foundational treatment to bring hope and impact to patients and families. #NiemannPickAwareness #NPC #RareDisease

@Zevratx is partnering with National Urea Cycle Disorders Foundation (NUCDF) for #CheckAmmonia Month. Together we want to raise awareness on the importance of prompt and accurate blood ammonia testing for diagnosing #UreaCycleDisorders. Learn more: bit.ly/3BOeoXI #UCDs #NUCDF

Zevra Therapeutics will provide third quarter 2025 financial results and business updates on Wednesday, November 5, 2025 and will host a webcast at 4:30 p.m. ET. For registration details, see the release: bit.ly/47r8UOR #IR #InvestorRelations

Want to join a purpose-driven company with a proven record of bringing new therapies to patients? We’re hiring! Be part of a team bringing life-changing therapies to people living with rare diseases. Explore open roles: zevra.com/careers/

This #NPCAwarenessMonth, we honor teens like Connor Martin, whose strength inspires us all. Connor’s journey with Niemann-Pick disease type C reminds us that every moment matters. Read his story via WCCO | CBS News Minnesota: bit.ly/4hvo3TG #NPCAwarenessMonth #RareDisease